MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Contact Us

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

Enpatoran Journal Publications

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

TLR7 and TLR8 Differently Activate the IRF and NF-KB Pathways in Specific Cell Types to Promote Inflammation.

Bender | Immunohorizons. 2020;4:93-107.

Towards a Novel Clinical Outcome Assessment for Systemic Lupus Erythematosus: First Outcomes of an International Taskforce.

Connelly | Nat Rev Rheumatol. 2023; 19:592-602.

Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases.

Deshmukh | Journal of Pharmacology and Experimental Therapeutics March 2024, 388 (3) 751-764.

Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Enpatoran for Indications of High Medical Need.

Klopp-Schulze | Clin Pharmacol Ther. 2022;112(2):297-306.

Enpatoran in COVID-19 Pneumonia: Safety and Efficacy Results From a Phase II Randomized Trial.

McKinnon | Clin Transl Sci. 2023;16(12):2640-2653.

Phase 1 Study in Healthy Participants of the Safety, Pharmacokinetics and Pharmacodynamics of M5049, a Dual Antagonist of Toll-Like Receptor 7 and 8.

Port | Pharmacol Res Perspect. 2021;9(5):e00842.

Exploring the Perspectives of Patients Living With Lupus: Retrospective Social Listening Study.

Spies | JMIR Form Res. 2024;8:e52768.

Discovery of M5049: a Novel Selective TLR7/8 Inhibitor for Treatment of Autoimmunity.

Vlach | J Pharmacol Exp Ther. 2021;376:397-409.

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: